Skip to main content
Premium Trial:

Request an Annual Quote

ACT Genomics Acquires MC Diagnostics

NEW YORK – Asian molecular diagnostic firm ACT Genomics announced on Tuesday that it has completed its acquisition of MC Diagnostics.

Financial terms of the deal were undisclosed.

The companies plan to develop fusion gene chips on MC Diagnostics' automated low density array platform, known as ALDAS, that can be performed at the point of care, ACT said in a statement. The first gene chip, called the ACTSpot NTRK, will be launched in August.

United Kingdom-based MC Diagnostics offers automated multiplex molecular tests and image analysis and interpretation software. The firm also offers HLA typing and blood group diagnostics on its ALDAS platform.

The ALDAS system has an eight-well strip array that allows up to 96 samples to be run at a time, with a turnaround time of three hours, ACT said.

Taipei-based ACT Genomics specializes in next-generation sequencing-based tests and oncology molecular diagnostics. The firm provides cancer treatment planning, immunotherapy evaluation, cancer relapse and drug resistance monitoring, and cancer risk assessment.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.